Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 4

2(28.6%)

7Total

Phase 1(5)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04868981Phase 1Completed

Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets

Role: lead

NCT05345964Phase 1Unknown

Phase I Study of GST-HG151 Tablets in Healthy Volunteers

Role: lead

NCT04499443Phase 1Unknown

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets

Role: lead

NCT04386915Phase 1Unknown

Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets

Role: lead

NCT04228406Phase 1Unknown

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161

Role: lead

NCT02360592Phase 4Completed

Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients

Role: collaborator

NCT01436539Phase 4Unknown

Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients

Role: collaborator

All 7 trials loaded